Predictive Oncology (POAI) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 12, 2017
Document Information [Line Items]
Entity Registrant Name	Skyline Medical Inc.
Entity Central Index Key	1,446,159
Trading Symbol	skln
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		6,189,428
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents	$ 2,086,408	$ 1,764,090
Certificates of Deposit	2,693,985	100,000
Marketable Securities		284,329
Accounts Receivable	68,506	38,919
Inventories	249,186	272,208
Prepaid Expense and other assets	160,282	148,637
Total Current Assets	5,258,367	2,608,183
Fixed Assets, net	112,709	101,496
Intangibles, net	95,172	97,867
Total Assets	5,466,248	2,807,546
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	79,264	220,112
Accrued Expenses	1,202,939	1,346,105
Deferred Revenue	14,407	7,998
Total Current Liabilities	1,296,610	1,574,215
Accrued Expenses	186,922	309,649
Total Liabilities	1,483,532	1,883,864
Commitments and Contingencies
Common Stock, $.01 par value, 24,000,000 authorized, 6,489,428 and 4,564,428 outstanding	64,894	45,644
Additional paid-in capital	(52,277,328)	(47,894,196)
Accumulated Deficit	48,360,298	47,018,451
Accumulated Other Comprehensive Income		1,501
Total Stockholders' Equity	3,982,716	923,682
Total Liabilities and Stockholders' Equity	5,466,248	2,807,546
Series B Convertible Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS' EQUITY
Series B Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 79,246 and 79,246 outstanding	$ 792	$ 792

Condensed Balance Sheets (Curr3

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	24,000,000	24,000,000
Common stock, shares outstanding (in shares)	6,489,428	4,564,428
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246

Condensed Statements of Operati

Condensed Statements of Operations and Other Comprehensive Income (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue	$ 175,166	$ 96,905
Cost of goods sold	36,992	85,883
Gross margin	138,174	11,022
General and administrative expense	1,132,073	1,688,577
Operations expense	200,494	390,366
Sales and marketing expense	147,454	108,448
Interest expense
Total Expense	1,480,021	2,187,391
Net loss available to common shareholders	(1,341,847)	(2,176,369)
Unrealized gain from marketable securities		2,850
Comprehensive loss	$ (1,341,847)	$ (2,173,519)
Loss per common share - basic and diluted (in dollars per share)	$ (0.21)	$ (3.01)
Weighted average shares used in computation - basic and diluted (in shares)	6,450,967	723,848

Statement of Stockholders' Equi

Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series B Warrants [Member]Common Stock [Member]	Series B Warrants [Member]Additional Paid-in Capital [Member]	Series B Warrants [Member]	Investment Banker [Member]Common Stock [Member]	Investment Banker [Member]Additional Paid-in Capital [Member]	Investment Banker [Member]	Investor Relations Consultant [Member]Common Stock [Member]	Investor Relations Consultant [Member]Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	GLG Pharma, LLC. [Member]Common Stock [Member]	GLG Pharma, LLC. [Member]	Former CEO [Member]Common Stock [Member]	Former CEO [Member]Additional Paid-in Capital [Member]	Former CEO [Member]	The 2016 Registered Direct Offering [Member]Common Stock [Member]	The 2016 Registered Direct Offering [Member]Additional Paid-in Capital [Member]	The 2016 Registered Direct Offering [Member]	Over-Allotment Option [Member]Common Stock [Member]	Over-Allotment Option [Member]Additional Paid-in Capital [Member]	Over-Allotment Option [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015																					$ 18,950	$ 2,080	$ 44,584,118	$ (40,492,437)		$ 4,112,711
Balance (in shares) at Dec. 31, 2015																						208,259
Shares issued for two options exercised at $65.75 per share (in shares)																						1,312
Shares issued for two options exercised at $65.75 per share																						$ 13	86,240			86,253
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering																					(18,158)	$ 664	17,494			0
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering (in shares)																						66,396
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering (in shares)	628,237																					2,318,663
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering	$ 6,282	$ 150,777	$ 157,059																			$ 23,187	556,479			579,666
Stock Issued During Period Shares Warrants Exercised	628,237																					2,318,663
Shares issued for cashless Series B warrant exercises per the tender offer exchange	$ 6,282	$ 150,777	$ 157,059																			$ 23,187	556,479			579,666
Stock Issued During Period, Shares, Issued for Services				135,995
Shares Issued				$ 1,360	$ 508,620	$ 509,980
Stock Issued During Period, Shares, New Issues							26,000			400,000		20,000			756,999
Stock Issued During Period, Value, New Issues							$ 260	$ 116,740	$ 117,000	$ 4,000	$ 4,000	$ 200	$ 90,151	$ 90,351	$ 7,570	$ 1,618,335	$ 1,625,905
Vesting Expense																							165,271			165,271
Unrealized gain from marketable securities																									$ 1,501	1,501
Corrections due to rounding for reverse split and DTCC increase (in shares)																						2,567
Corrections due to rounding for reverse split and DTCC increase																						$ 28	(29)			(1)
Net loss																								(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																					792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																						4,564,428
Stock Issued During Period, Shares, New Issues																		175,000				1,750,000
Stock Issued During Period, Value, New Issues																		$ 1,750	$ 392,000	$ 393,750		$ 17,500	3,403,688			3,421,188
Vesting Expense																							587,444			587,444
Unrealized gain from marketable securities																									$ (1,501)
Net loss																								(1,341,847)		(1,341,847)
Balance at Mar. 31, 2017																					$ 792	$ 64,894	$ 52,277,328	$ (48,360,298)		$ 3,982,716
Balance (in shares) at Mar. 31, 2017																						6,489,428

Statement of Stockholders' Equ6

Statement of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2016	Aug. 31, 2015
Investment Banker [Member]
Price of shares issued (in dollars per share)	$ 3.75
Investor Relations Consultant [Member]
Price of shares issued (in dollars per share)	4.50
Former CEO [Member]
Price of shares issued (in dollars per share)	4.50
Options exercise price (in dollars per share)	$ 65.75
Price of shares issued (in dollars per share)		$ 9

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flow from operating activities:
Net loss	$ (1,341,847)	$ (2,176,369)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,574	21,040
Vested stock options and warrants	587,444	37,775
Issuance of common stock in cashless warrant exchange		468,158
Loss on Sales of Equipment		145
Gain from sale of marketable securities	(1,837)
Changes in assets and liabilities:
Accounts receivable	(29,587)	(14,495)
Inventories	23,022	(24,791)
Prepaid expense and other assets	(11,645)	100,690
Accounts payable	(140,848)	141,271
Accrued expenses	(265,893)	(141,306)
Deferred Revenue	6,409
Net cash used in operating activities:	(1,156,208)	(1,587,882)
Cash flow from investing activities:
Purchase of marketable securities		(800,000)
Proceeds from sale of marketable securities	284,665
Purchase of certificates of deposit	(2,593,985)	(1,000,000)
Purchase of fixed assets	(26,898)	(17,387)
Purchase of intangibles	(194)	(1,424)
Net cash used in investing activities:	(2,336,412)	(1,818,811)
Cash flow from financing activities:
Issuance of common stock	3,814,938	86,253
Net cash provided by (used in) financing activities	3,814,938	86,253
Net increase (decrease) in cash	322,318	(3,320,440)
Cash at beginning of period	1,764,090	4,856,232
Cash at end of period	$ 2,086,408	$ 1,535,792

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. August 6, 2013, March 31, 2017, 6,489,428 $.01 1 25 October 27, 2016. December 16, 2013, April 2009, 510(k) The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 Since inception to March 31, 2017, $27,765,934 $2,055,000 $13,555,003 2015, $1,739,770 2016, $3,421,188 first 2017, $358,312 175,000 35,000 $5,685,000 Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.”. December 15, 2017, two 606. January 1, 2018, In June 2014, 2014 12, "Compensation - Stock Compensation" In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In April 2015, 2015 03, Simplifying the Presentation of Debt Issuance Costs 2015 03 In July 2015, 2015 11 , Inventory (Topic 330): December 15, 2016, In November 2015, 2015 17, “Income Taxes (Topic 740)” December 15, 2016 In January 2016, 2016 01, “Financial Instruments-Overall (Subtopic 825 10): 2016 01”). December 15, 2017, In February 2016, 2016 02, Leases (Topic 842) 2016 02”), December 15, 2018. In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718): 2016 09”). 2016 09 December 15, 2016. During August 2016, 2016 15, “Statement of Cash Flows (Topic 230): December 15, 2017, 2016 15 We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may may Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $4,271 three March 31, 2017 $3,996 three March 31, 2016. Research and Development Research and development costs are charged to operations as incurred. Research and development expenses were $84,472 three March 31, 2017 $122,161 three March 31, 2016. Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 605 Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY SYSTEM units as well as shipments of filters and fluids. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one may Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest bearing investments are those with maturities of less than one three one Investment Securities Readily marketable investments in debt and equity securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Codification 820, 820 three Level 1 Level 2 Level 3 The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first March 31, December 31, Finished goods $ 28,003 $ 38,201 Raw materials 159,972 165,812 Work-In-Process 61,211 68,195 Total $ 249,186 $ 272,208 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: March 31, December 31, Computers and office equipment $ 176,360 $ 164,318 Leasehold improvements 25,635 25,635 Manufacturing tooling 103,204 103,204 Demo Equipment 38,092 23,236 Total 343,291 316,393 Less: Accumulated depreciation 230,582 214,897 Total Fixed Assets, Net $ 112,709 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $15,685 three March 31, 2017, $19,207 three March 31, 2016. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $2,888 three March 31, 2017, $1,832 three March 31, 2016. Income Taxes The Company accounts for income taxes in accordance with ASC 740 740”). 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no Tax years subsequent to 2013 Summary of Significant Accounting Policies In March 2016, 2016 09, 2016 09 December 15, 2016, 2016 09, The adoption of ASU 2016 09 Income Tax Balance Sheet Classification In November 2015, 2015 17, 740)” December 15, 2016 2015 17 Patents and Intellectual Property On January 25th, 2014, PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 US20090216205 August 8, 2023. In July 2015, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $1,866,875 Product Warranty Costs In the three March 31, 2017, $4,343 $29,889 three March 31, 2016. Segments The Company operates in two three March 31, 2017 2016 first March 2017. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies. Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 March 15, 2017. may

Note 2 - Stockholders' Equity (

Note 2 - Stockholders' Equity (Deficit), Stock Options and Warrants	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 2 The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten 2015 On August 31, 2015 1,666,667 $9.00 $8.28 $0.72 8.00%) $13.8 45 250,000 1% $70,000. On August 31, 2015, 228,343 1,895,010 75,801 1,895,010 7,580,040 Each Unit consisted of one $0.01 one four February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants August 31, 2020. one $123.75 Holders may Total Shares = (A x B) / C Where: · Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black-Scholes Value (as defined below). · C is the closing bid price of the Common Stock as of two may $0.43 The Black-Scholes Value (as defined above) as of September 30, 2016 $4.319, September 30, 2016, $4.125. 40 6,141,115 September 30, 2016, 2,318,663 35,084 August 31, 2015 two $0.43 $4.319 September 30, 2016), 564 The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% 13(d) 1934, In addition to (but not duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the three (1) (2) Unit Purchase Option. August 31, 2015 5% 83,333 125% $11.25 May 2016 135,995 Series B Preferred Stock. one six 4.99% Unit Exchange. February 4, 2014, $2,055,000 20,550 $0.01, $100 February 4, 2014. August 31, 2015, 228,343 3,991 3(a)(9) August 31, 2015, Redemption of Convertible Notes. $933,074 40% $1,548,792. 3. $167,031 Registered Exchange Offer for Warrants. March 25, 2016, $0.01 3,157,186 March 31, 2016, 10.05 may one tendered 10.2 one April 21, 2016. 1,770,556 tendered 18,059,671 March 31, 2016 July 6, 2016 1,251,510 20,122 2016 On November 29, 2016, $1,983,337. 756,999 $2.62 five 756,999 six $4.46 $1,739,770. 2017 On January 13, 2017, 1,750,000 $2.25 one 0.2 one $2.25 $3,937,500 45 175,000 35,000 $0.01 January 19, 2017. February 22, 2017, $358,312. The Company’s stockholders’ equity now exceeds $2.5 February 15, 2017, Accounting for share-based payment The Company has adopted ASC 718 718"). 718 January 1, 2006 January 1, 2006. January 1, 2006, ASC 718 Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2015, $487.50 $243.75 125 16 On March 31, 2015, 6% $243.75 125 16 On June 30, 2015, 6% $243.75 125 16 For grants of stock options and warrants in 2015 1.63% 2.35% 0% 59% 66% 5 10 $6.875 $139.2375 On March 25, 2016, April 20, 2016, On July 1, 2016, 40,000 $0.01 $3.75 six first, second, third, fourth, fifth sixth On October 4, 2016, 400,000 $0.01, For grants of stock options and warrants in 2016 1.46% 2.45% 0% 59% 66% 5 10 $1.6329 $3.7195 For grants of stock option and warrants in 2017 1.92% 2.40% 0% 59% 66% 5 10 $1.0293 $1.5489 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Exercise Price Number of Average Price Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 14,286 2.10 385,000 2.25 Expired (8,472 ) 10.41 - - Exercised - - - - Outstanding at March 31, 2017 171,457 $ 10.50 1,256,101 $ 36.90 At March 31, 2017, 112,263 $14.13 9.45 499,102 three March 2017 March 2016 $99,307 $37,775, $155,514 9 The following summarizes the status of options and warrants outstanding at March 31, 2017: Range of Prices Shares Weighted Remaining Life Options $ 2.10 14,286 10.00 $ 2.25 293 9.41 $ 2.42 28,896 9.39 $ 2.80 57,145 9.76 $ 3.75 44,000 9.26 $ 4.125 3,636 9.51 $ 4.1975 7,147 9.47 $ 4.25 3,529 9.01 $ 5.125 3,902 9.44 $ 65.75 266 8.56 $ 73.50 1,157 8.76 $ 77.50 2,323 8.25 $ 80.25 187 8.51 $ 86.25 232 8.01 $ 131.25 81 5.44 $ 148.125 928 5.97 $ 150.00 1,760 5.38 $ 162.50 123 7.76 $ 206.25 121 7.51 $ 248.4375 121 6.29 $ 262.50 130 6.29 $ 281.25 529 5.80 $ 318.75 3 6.11 $ 346.875 72 7.01 $ 431.25 306 6.94 $ 506.25 188 6.76 $ 543.75 53 6.52 $ 596.25 42 6.50 171,457 Warrants $ 2.25 385,000 4.82 $ 4.46 756,999 4.67 $ 93.75 2,255 0.95 $ 123.75 94,084 3.42 $ 150.00 4,114 0.95 $ 225.00 107 0.82 $ 243.75 2,529 2.35 $ 281.25 5,897 0.70 $ 309.375 2,850 2.36 $ 309.50 222 2.61 $ 337.50 178 1.22 $ 371.25 944 1.16 $ 506.25 59 1.88 $ 609.375 862 1.85 1,256,101 Stock options and warrants expire on various dates from June 2017 March 2027. At a special meeting of stockholders held on September 15, 2016, 100,000,000 200,000,000 September 16, 2016, October 26, 2106, one twenty five (1:25), 200,000,000 8,000,000 5:00 October 27, 2016, October 28, 2016. may January 29, 2017. 8,000,000 24,000,000 Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of March 31, 2017 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,606 148.125 – 596.25 2014 835 162.50 – 431.25 2015 4,164 65.75 – 86.25 2016 148,551 2.25 – 5.13 2017 14,286 2.10 Total 171,457 $2.10 – 596.25 Warrants: Year Shares Price 2012 2,792 $281.25 2013 10,703 93.75 - 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 385,000 2.25 Total 1,256,101 $0.00 – 609.38

Note 3 - Short-term Notes Payab

Note 3 - Short-term Notes Payable	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Short-term Debt [Text Block]	NOTE 3 From July September 2014, $1.8 $1.6 “2014 $1,475,000. $122,196 2014 5,431 $100,000. April May 2015, $275,000 $250,000, 2014 “2015 2014 2015 Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, 11%, $1,603,260 11%, 2,851 In connection with the Offering, the holders of the Convertible Notes agreed to not exercise their right to convert the Convertible Notes into shares of the Company’s common stock, in exchange for the Company’s agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Offering at a redemption price equal to 140% August 31, 2015, $933,074 40% $1,548,792. $167,031 March 31, 2017,

Note 4 - Loss Per Share

Note 4 - Loss Per Share	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 4 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended March 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (1,341,847 ) $ (2,176,369 ) Other comprehensive income: Unrealized gain from marketable securities - 2,850 Comprehensive (loss) (1,341,847 ) (2,173,519 ) Denominator: Weighted average common shares outstanding-basic 6,450,967 723,848 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,450,967 723,848 Loss per common share-basic and diluted $ (0.21 ) $ (3.01 ) (1) March 31, 2017 March 31, 2016 1,427,558 167,986 March 31, 2017 79,246.

Note 5 - Income Taxes

Note 5 - Income Taxes	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 5 The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which whose temporary differences are expected to be recovered or settled. There is no income tax provision in the accompanying statements of operations and comprehensive income due to the cumulative operating losses that indicate 100% During September 2013, 382 may September 2013, At December 31, 2016, $30.9 2017, 382 2022 $13.0 December 31, 2016, 2022 2036 December 31, 2016, $10.7 $0.2 At March 31, 2017, $31.4 2018, 382 2022 $13.2 March 31, 2017, 2022 2037 March 31, 2017, $11.0 $0.2 The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at March 31, 2017 December 31, 2016 March 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,865,000 $ 10,755,000 Other 343,000 189,000 Total Deferred Tax Asset 11,208,000 10,944,000 Less Valuation Allowance 11,208,000 10,944,000 Net Deferred Income Taxes $ — $ —

Note 6 - Rent Obligation

Note 6 - Rent Obligation	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	NOTE 6 The Company leases its principal office under a lease that can be cancelled after three five January 2018. $16,895 $16,750 three March 31, 2017 March 31, 2016 The Company’s rent obligation for the next two 2017 $ 29,250 2018 $ 3,000

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 7 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, 400,000 four 100,000 November 1, 2016, November 2, 2016, April 2017,

Note 8 - Retirement Savings Pla

Note 8 - Retirement Savings Plan	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 8 We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) 2017 2016, 100%, 4% $9,770 $11,117 three March 31, 2017 March 31, 2016,

Note 9 - Subsequent Events

Note 9 - Subsequent Events	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 9 In April 2017, On April 24, 2017, 100,000 $0.01,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. August 6, 2013, March 31, 2017, 6,489,428 $.01 1 25 October 27, 2016. December 16, 2013, April 2009, 510(k) The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 Since inception to March 31, 2017, $27,765,934 $2,055,000 $13,555,003 2015, $1,739,770 2016, $3,421,188 first 2017, $358,312 175,000 35,000 $5,685,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.”. December 15, 2017, two 606. January 1, 2018, In June 2014, 2014 12, "Compensation - Stock Compensation" In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In April 2015, 2015 03, Simplifying the Presentation of Debt Issuance Costs 2015 03 In July 2015, 2015 11 , Inventory (Topic 330): December 15, 2016, In November 2015, 2015 17, “Income Taxes (Topic 740)” December 15, 2016 In January 2016, 2016 01, “Financial Instruments-Overall (Subtopic 825 10): 2016 01”). December 15, 2017, In February 2016, 2016 02, Leases (Topic 842) 2016 02”), December 15, 2018. In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718): 2016 09”). 2016 09 December 15, 2016. During August 2016, 2016 15, “Statement of Cash Flows (Topic 230): December 15, 2017, 2016 15 We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may may
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Presentation of Taxes Collected From Customers, Policy [Policy Text Block]	Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
Advertising Costs, Policy [Policy Text Block]	Advertising Advertising costs are expensed as incurred. Advertising expenses were $4,271 three March 31, 2017 $3,996 three March 31, 2016.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development expenses were $84,472 three March 31, 2017 $122,161 three March 31, 2016.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 605 Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY SYSTEM units as well as shipments of filters and fluids. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Certificates of Deposit Policy [Policy Text Block]	Certificates of Deposit Short-term interest bearing investments are those with maturities of less than one three one
Marketable Securities, Policy [Policy Text Block]	Investment Securities Readily marketable investments in debt and equity securities are classified as available-for-sale and are reported at fair value with unrealized gains and losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Codification 820, 820 three Level 1 Level 2 Level 3 The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1
Receivables, Policy [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first March 31, December 31, Finished goods $ 28,003 $ 38,201 Raw materials 159,972 165,812 Work-In-Process 61,211 68,195 Total $ 249,186 $ 272,208
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: March 31, December 31, Computers and office equipment $ 176,360 $ 164,318 Leasehold improvements 25,635 25,635 Manufacturing tooling 103,204 103,204 Demo Equipment 38,092 23,236 Total 343,291 316,393 Less: Accumulated depreciation 230,582 214,897 Total Fixed Assets, Net $ 112,709 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $15,685 three March 31, 2017, $19,207 three March 31, 2016.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $2,888 three March 31, 2017, $1,832 three March 31, 2016.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 740”). 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no Tax years subsequent to 2013
Newly Adopted Accounting Standards, Policy [Policy Text Block]	Summary of Significant Accounting Policies In March 2016, 2016 09, 2016 09 December 15, 2016, 2016 09, The adoption of ASU 2016 09 Income Tax Balance Sheet Classification In November 2015, 2015 17, 740)” December 15, 2016 2015 17
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Intellectual Property On January 25th, 2014, PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 US20090216205 August 8, 2023. In July 2015,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $1,866,875
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty Costs In the three March 31, 2017, $4,343 $29,889 three March 31, 2016.
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in two three March 31, 2017 2016 first March 2017.
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 March 15, 2017. may

Note 1 - Summary of Significa18

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, Finished goods $ 28,003 $ 38,201 Raw materials 159,972 165,812 Work-In-Process 61,211 68,195 Total $ 249,186 $ 272,208
Property Plant and Equipment UsefulLife [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo Equipment 3
Property, Plant and Equipment [Table Text Block]	March 31, December 31, Computers and office equipment $ 176,360 $ 164,318 Leasehold improvements 25,635 25,635 Manufacturing tooling 103,204 103,204 Demo Equipment 38,092 23,236 Total 343,291 316,393 Less: Accumulated depreciation 230,582 214,897 Total Fixed Assets, Net $ 112,709 $ 101,496

Note 2 - Stockholders' Equity19

Note 2 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Average Exercise Price Number of Average Price Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 14,286 2.10 385,000 2.25 Expired (8,472 ) 10.41 - - Exercised - - - - Outstanding at March 31, 2017 171,457 $ 10.50 1,256,101 $ 36.90
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 2.10 14,286 10.00 $ 2.25 293 9.41 $ 2.42 28,896 9.39 $ 2.80 57,145 9.76 $ 3.75 44,000 9.26 $ 4.125 3,636 9.51 $ 4.1975 7,147 9.47 $ 4.25 3,529 9.01 $ 5.125 3,902 9.44 $ 65.75 266 8.56 $ 73.50 1,157 8.76 $ 77.50 2,323 8.25 $ 80.25 187 8.51 $ 86.25 232 8.01 $ 131.25 81 5.44 $ 148.125 928 5.97 $ 150.00 1,760 5.38 $ 162.50 123 7.76 $ 206.25 121 7.51 $ 248.4375 121 6.29 $ 262.50 130 6.29 $ 281.25 529 5.80 $ 318.75 3 6.11 $ 346.875 72 7.01 $ 431.25 306 6.94 $ 506.25 188 6.76 $ 543.75 53 6.52 $ 596.25 42 6.50 171,457 Warrants $ 2.25 385,000 4.82 $ 4.46 756,999 4.67 $ 93.75 2,255 0.95 $ 123.75 94,084 3.42 $ 150.00 4,114 0.95 $ 225.00 107 0.82 $ 243.75 2,529 2.35 $ 281.25 5,897 0.70 $ 309.375 2,850 2.36 $ 309.50 222 2.61 $ 337.50 178 1.22 $ 371.25 944 1.16 $ 506.25 59 1.88 $ 609.375 862 1.85 1,256,101
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,606 148.125 – 596.25 2014 835 162.50 – 431.25 2015 4,164 65.75 – 86.25 2016 148,551 2.25 – 5.13 2017 14,286 2.10 Total 171,457 $2.10 – 596.25 Warrants: Year Shares Price 2012 2,792 $281.25 2013 10,703 93.75 - 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 385,000 2.25 Total 1,256,101 $0.00 – 609.38

Note 4 - Loss Per Share (Tables

Note 4 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (1,341,847 ) $ (2,176,369 ) Other comprehensive income: Unrealized gain from marketable securities - 2,850 Comprehensive (loss) (1,341,847 ) (2,173,519 ) Denominator: Weighted average common shares outstanding-basic 6,450,967 723,848 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,450,967 723,848 Loss per common share-basic and diluted $ (0.21 ) $ (3.01 )

Note 5 - Income Taxes (Tables)

Note 5 - Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	March 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,865,000 $ 10,755,000 Other 343,000 189,000 Total Deferred Tax Asset 11,208,000 10,944,000 Less Valuation Allowance 11,208,000 10,944,000 Net Deferred Income Taxes $ — $ —

Note 6 - Rent Obligation (Table

Note 6 - Rent Obligation (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Rent Expense [Table Text Block]	2017 $ 29,250 2018 $ 3,000

Note 1 - Summary of Significa23

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Feb. 22, 2017USD ($)	Jan. 19, 2017shares	Nov. 29, 2016USD ($)	Oct. 27, 2016	Aug. 31, 2015USD ($)	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Oct. 04, 2016$ / shares
Common Stock, Shares, Outstanding | shares						6,489,428		4,564,428		4,564,428	6,489,428
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.01		$ 0.01		$ 0.01	$ 0.01	$ 0.01
Stockholders' Equity, Period Increase (Decrease)						$ 27,765,934
Stock Issued During Period, Value, New Issues						3,421,188
Proceeds from Issuance or Sale of Equity					$ 13,800,000
Debt Instrument, Increase (Decrease), Net											$ 5,685,000
Advertising Expense						4,271	$ 3,996
Research and Development Expense						84,472	122,161
Depreciation						15,685	19,207
Amortization of Intangible Assets						2,888	1,832
Income Tax Expense (Benefit)						$ 0
Valuation Allowance Percentage						100.00%
Unrecognized Tax Benefits						$ 0					0
Cash, Uninsured Amount						1,866,875					1,866,875
Product Warranty Expense						$ 4,343	$ 29,889
Number of Operating Segments						2
Earliest Tax Year [Member]
Open Tax Year						2,013
IPO [Member]
Stock Issued During Period, Value, New Issues									$ 13,555,003		3,421,188
The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues								$ 1,625,905
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 1,739,770							$ 1,739,770
Proceeds from Issuance or Sale of Equity			$ 1,983,337
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues						$ 393,750
Proceeds from Issuance or Sale of Equity	$ 358,312
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase | shares		175,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase | shares		35,000
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues											$ 2,055,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				25

Note 1 - Summary of Significa24

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Finished goods	$ 28,003	$ 38,201
Raw materials	159,972	165,812
Work-In-Process	61,211	68,195
Total	$ 249,186	$ 272,208

Note 1 - Summary of Significa25

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	3 Months Ended
	Mar. 31, 2017
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significa26

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Property, Plant, and Equipment Gross	$ 343,291	$ 316,393
Less: Accumulated depreciation	230,582	214,897
Total Fixed Assets, Net	112,709	101,496
Office Equipment [Member]
Property, Plant, and Equipment Gross	176,360	164,318
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	25,635	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	103,204	103,204
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 38,092	$ 23,236

Note 2 - Stockholders' Equity27

Note 2 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual)	Feb. 22, 2017USD ($)	Jan. 19, 2017USD ($)$ / sharesshares	Nov. 29, 2016USD ($)$ / sharesshares	Oct. 27, 2016	Oct. 04, 2016$ / sharesshares	Jul. 01, 2016$ / sharesshares	Mar. 31, 2016shares	Aug. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2015$ / sharesshares	Mar. 31, 2015$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	May 31, 2016shares	Jan. 31, 2015$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Jul. 06, 2016shares	Mar. 31, 2016USD ($)	Sep. 30, 2016$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015$ / shares	Dec. 31, 2016USD ($)$ / sharesshares	Oct. 26, 2016shares	Sep. 15, 2016shares	Sep. 14, 2016shares	Apr. 21, 2016shares	Mar. 25, 2016$ / sharesshares
Shares Issued, Price Per Share | $ / shares								$ 9
Underwriter Price | $ / shares								8.28
Underwriting Discount | $ / shares								$ 0.72
Underwriting Commission								8.00%
Proceeds from Issuance or Sale of Equity | $								$ 13,800,000
Option Granted to Underwriter to Purchase Additional Units Period								45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted								250,000
Underwriting Agreement Non-accountable Expense Allowance Percentage								1.00%
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.01									$ 0.01				$ 0.01		$ 0.01
Share Price | $ / shares																	$ 4.125
Class of Warrant or Right, Outstanding														1,256,101
Stock Issued During Period, Value, New Issues | $														$ 3,421,188
Stock Issued During Period, Shares, New Issues					400,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate														0.00%				0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum														59.00%				59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum														66.00%				66.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number														112,263
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares														$ 14.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term														9 years 164 days
Class of Warrant or Right Number of Warrants Vested and Exercisable														499,102
Allocated Share-based Compensation Expense | $														$ 99,307		$ 37,775
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $														$ 155,514
Common Stock, Shares Authorized														24,000,000				24,000,000		24,000,000	8,000,000	200,000,000	100,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				25
Purchasers [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									125	125			125
Preferred Stock Conversion Price Per Share | $ / shares													$ 487.50
Conversion of Stock Price Per Share | $ / shares									$ 243.75	$ 243.75			$ 243.75
Number of Preferred Stock Share holders									16	16			16
Preferred Stock, Dividend Rate, Percentage									6.00%	6.00%
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.01
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares						$ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						40,000
Number of Equal Installments Options are Expected to Vest						6
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity | $			$ 1,983,337
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 4.46
Share Price | $ / shares			$ 2.62
Stock Issued During Period, Value, New Issues | $																		$ 1,625,905
Stock Issued During Period, Shares, New Issues			756,999
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			756,999
Class of Warrant or Right Term			5 years
Class of Warrant or Right, Vesting Period			180 days
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $			$ 1,739,770																	$ 1,739,770
The 2017 Public Offering [Member]
Proceeds from Issuance or Sale of Equity | $		$ 3,937,500
Share Price | $ / shares		$ 2.25
Stock Issued During Period, Shares, New Issues		1,750,000
Share Per Each Unit		1
Over-Allotment Option [Member]
Proceeds from Issuance or Sale of Equity | $	$ 358,312
Stock Issued During Period, Value, New Issues | $														$ 393,750
Sale of Stock, Underwriter Option Term		45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase		175,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase		35,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares		$ 0.01
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount | $								$ 933,074
Debt Instrument Redemption Premium Percentage								40.00%
Debt Instrument Redemption Price | $								$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates | $								$ 167,031
Series B Convertible Preferred Stock [Member]
Beneficial Ownership Limitation Percentage								4.99%
Stock Issued During Period, Value, New Issues | $											$ 2,055,000
Stock Issued During Period, Shares, New Issues											20,550
Preferred Stock Par Value | $ / shares											$ 0.01
Preferred Stock Stated Value | $ / shares											$ 100
Series A Warrants [Member] | Exchange Offer [Member]
Stock to be Issued for Exchange Offer, Shares, Maximum																									3,157,186
Cashless Exercise of Common Stock Warrants, Total							10.05
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								1,770,556
Exchange from Series B Warrants to Warrant Shares [Member] | Exchange Offer [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																									$ 0.01
Series B Warrants [Member] | Exchange Offer [Member]
Class of Warrant or Right Exercised During Period															1,251,510
Stock Issued During Period Shares Warrants Exercised															20,122
Cashless Exercise of Common Stock Warrants, Total							10.2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								18,059,671
Series D Warrants [Member] | The 2017 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 2.25
Class of Warrant or Right, Issued per Unit		0.2
Common Stock [Member]
Stock Issued During Period Shares Warrants Exercised																		2,318,663
Stock Issued During Period, Value, New Issues | $														$ 17,500
Stock Issued During Period, Shares, New Issues														1,750,000
Common Stock [Member] | The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues | $																		$ 7,570
Stock Issued During Period, Shares, New Issues																		756,999
Common Stock [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues | $														$ 1,750
Stock Issued During Period, Shares, New Issues														175,000
Common Stock [Member] | Series B Warrants [Member]
Stock Issued During Period Shares Warrants Exercised																		628,237
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit								1
Common Stock, Par or Stated Value Per Share | $ / shares								$ 0.01
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								1									0.4
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 123.75
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise								2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula | $ / shares								$ 0.43
Warrants Option to Settle in Cash Fair Value Disclosure | $ / shares																	$ 4.319
Class of Warrant or Right Exercised During Period																	6,141,115
Stock Issued During Period Shares Warrants Exercised																	2,318,663
Class of Warrant or Right, Outstanding								35,084
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise | $ / shares								$ 0.43
Beneficial Ownership Limitation Percentage								4.99%
Class of Warrant or Right Period Over Which Additional Adjustments to Price and Number of Shares May Be Made								3 years
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period Shares Warrants Exercised																	564
Corporate Stock Transfer Inc. [Member] | Series B Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit								1
Corporate Stock Transfer Inc. [Member] | Series A Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit								4
Exchange Units [Member]
Unit Purchase Option Units Sold								1,666,667
Stock Issued During Period, Shares, Conversion of Convertible Securities								1,895,010
Exchange Units [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities								3,991
Exchange Units [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities								7,580,040
Exchange Units [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities								75,801
Exchange Units [Member] | Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities								1,895,010
Exchange Units [Member] | Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued								228,343
Stock Issued During Period, Shares, Conversion of Convertible Securities												135,995
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage								5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase								83,333
Unit Purchase Option Exercise Price, Percentage								125.00%
Unit Purchase Option Exercise Price | $ / shares								$ 11.25
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period														3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														10 years
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter | $								$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 609.38
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate														2.40%				2.45%	2.35%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																			10 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares														$ 596.25					$ 139.2375
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term														10 years				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares														$ 1.5489				$ 3.7195
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate														1.92%				1.46%	1.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term														5 years				5 years	5 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares														$ 2.10					$ 6.875
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares														$ 1.0293				$ 1.6329

Note 2 - Stockholders' Equity28

Note 2 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Number of Shares Expired (in shares)	(8,472)
Average Exercise Price Expired (in dollars per share)	$ 10.41
Number of Shares Expired (in shares)
Options exercise price (in dollars per share)		$ 65.75
Number of Shares Outstanding (in shares)	171,457
Number of Shares Expired (in shares)
Warrant [Member]
Number of Shares Outstanding (in shares)	871,101	323,099
Average Exercise Price Outstanding (in dollars per share)	$ 52.22	$ 128.40
Number of Shares Issued (in shares)	385,000	1,487,881
Average Exercise Price Issued (in dollars per share)	$ 2.25	$ 0.71
Number of Shares Expired (in shares)
Number of Shares Exercised (in shares)		(939,879)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	1,256,101	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 36.90	$ 52.22
Number of Shares Expired (in shares)
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	165,643	31,350
Average Exercise Price Outstanding (in dollars per share)	$ 11.22	$ 133.23
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	14,286	157,982
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 2.10	$ 3.14
Number of Shares Expired (in shares)		(22,377)
Average Exercise Price Expired (in dollars per share)		$ 122.13
Number of Shares Exercised (in shares)		(1,312)
Options exercise price (in dollars per share)		$ 65.75
Number of Shares Outstanding (in shares)	171,457	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 10.50	$ 11.22

Note 2 - Stockholders' Equity29

Note 2 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Shares, options (in shares)	171,457
Shares, warrants (in shares)	1,256,101
Warrant One [Member]
Price, warrants (in dollars per share) | $ / shares	$ 2.25
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	4 years 299 days
Warrant Two [Member]
Price, warrants (in dollars per share) | $ / shares	$ 4.46
Shares, warrants (in shares)	756,999
Weighted average remaining life, warrants (Year)	4 years 244 days
Warrant Three [Member]
Price, warrants (in dollars per share) | $ / shares	$ 93.75
Shares, warrants (in shares)	2,255
Weighted average remaining life, warrants (Year)	346 days
Warrant Four [Member]
Price, warrants (in dollars per share) | $ / shares	$ 123.75
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	3 years 153 days
Warrant Five [Member]
Price, warrants (in dollars per share) | $ / shares	$ 150
Shares, warrants (in shares)	4,114
Weighted average remaining life, warrants (Year)	346 days
Warrant Six [Member]
Price, warrants (in dollars per share) | $ / shares	$ 225
Shares, warrants (in shares)	107
Weighted average remaining life, warrants (Year)	299 days
Warrant Seven [Member]
Price, warrants (in dollars per share) | $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	2 years 127 days
Warrant Eight [Member]
Price, warrants (in dollars per share) | $ / shares	$ 281.25
Shares, warrants (in shares)	5,897
Weighted average remaining life, warrants (Year)	255 days
Warrant Nine [Member]
Price, warrants (in dollars per share) | $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	2 years 131 days
Warrant Ten [Member]
Price, warrants (in dollars per share) | $ / shares	$ 309.50
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	2 years 222 days
Warrant Eleven [Member]
Price, warrants (in dollars per share) | $ / shares	$ 337.50
Shares, warrants (in shares)	178
Weighted average remaining life, warrants (Year)	1 year 80 days
Warrant Twelve [Member]
Price, warrants (in dollars per share) | $ / shares	$ 371.25
Shares, warrants (in shares)	944
Weighted average remaining life, warrants (Year)	1 year 58 days
Warrant Thirteen [Member]
Price, warrants (in dollars per share) | $ / shares	$ 506.25
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	1 year 321 days
Warrant Fourteen [Member]
Price, warrants (in dollars per share) | $ / shares	$ 609.375
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	1 year 310 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.10
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	10 years
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	9 years 149 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.42
Shares, options (in shares)	28,896
Weighted average remaining life, options (Year)	9 years 142 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	9 years 277 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 3.75
Shares, options (in shares)	44,000
Weighted average remaining life, options (Year)	9 years 94 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	9 years 186 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	9 years 171 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	9 years 3 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	9 years 160 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 65.75
Shares, options (in shares)	266
Weighted average remaining life, options (Year)	8 years 204 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	8 years 277 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	8 years 91 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	8 years 186 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	5 years 160 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	5 years 354 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	5 years 138 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	7 years 277 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	7 years 186 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 105 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	6 years 105 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	5 years 292 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	6 years 40 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	6 years 343 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	6 years 277 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 543.75
Shares, options (in shares)	53
Weighted average remaining life, options (Year)	6 years 189 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	6 years 182 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares
Shares, options (in shares)	171,457
Weighted average remaining life, options (Year)

Note 2 - Stockholders' Equity30

Note 2 - Stockholders' Equity (Deficit), Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2015
Shares, options (in shares)	171,457
Shares, warrants (in shares)	1,256,101
Minimum [Member]
Price, options (in dollars per share)	$ 2.10	$ 6.875
Price, warrants (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25	$ 139.2375
Price, warrants (in dollars per share)	$ 609.38
Warrants 2012 [Member]
Shares, warrants (in shares)	2,792
Price, warrants (in dollars per share)	$ 281.25
Warrants 2013 [Member]
Shares, warrants (in shares)	10,703
Warrants 2013 [Member] | Minimum [Member]
Price, warrants (in dollars per share)	$ 93.75
Warrants 2013 [Member] | Maximum [Member]
Price, warrants (in dollars per share)	$ 371.25
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455
Warrants 2014 [Member] | Minimum [Member]
Price, warrants (in dollars per share)	$ 243.75
Warrants 2014 [Member] | Maximum [Member]
Price, warrants (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares)	94,152
Warrants 2015 [Member] | Minimum [Member]
Price, warrants (in dollars per share)	$ 0
Warrants 2015 [Member] | Maximum [Member]
Price, warrants (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares)	756,999
Price, warrants (in dollars per share)	$ 4.46
Warrants 2017 [Member]
Shares, warrants (in shares)	385,000
Price, warrants (in dollars per share)	$ 2.25
Stock Options 2011 [Member]
Shares, options (in shares)	173
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares)	1,841
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares)	1,606
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 148.125
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares)	835
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares)	4,164
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares)	148,551
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares)	14,286
Price, options (in dollars per share)	$ 2.10

Note 3 - Short-term Notes Pay31

Note 3 - Short-term Notes Payable (Details Textual) - USD ($)	Aug. 31, 2015	May 31, 2015	Mar. 31, 2017	Sep. 30, 2014	Sep. 09, 2014
The 2014 Convertible Notes [Member]
Debt Instrument, Face Amount				$ 1,800,000
Debt Instrument Reduced Face Amount				1,600,000	$ 1,603,260
Proceeds from Convertible Debt				1,475,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,851
Percentage Reduction to Debt Instrument Face Amount					11.00%
Percentage Reduction to Number of Warrants					11.00%
The 2014 Convertible Notes [Member] | SOK Partners LLC [Member]
Debt Instrument, Face Amount				122,196
Proceeds from Convertible Debt				$ 100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				5,431
The 2015 Convertible Notes [Member]
Debt Instrument, Face Amount		$ 275,000
Proceeds from Convertible Debt		$ 250,000
Class of Warrant or Right Issued During Period		0
The Convertible Notes [Member]
Debt Instrument, Redemption Price, Percentage			140.00%
Debt Instrument Redemption Principal Amount	$ 933,074
Debt Instrument Redemption Premium Percentage	40.00%
Debt Instrument Redemption Price	$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates	$ 167,031
Short-term Debt			$ 0

Note 4 - Loss Per Share (Detail

Note 4 - Loss Per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,427,558	167,986
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 4 - Loss Per Share - Share

Note 4 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		12 Months Ended
		Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Net loss available in basic and diluted calculation		$ (1,341,847)	$ (2,176,369)	$ (6,526,014)
Unrealized gain from marketable securities			2,850	$ 1,501
Comprehensive (loss)		$ (1,341,847)	$ (2,173,519)
Weighted average common shares outstanding-basic (in shares)		6,450,967	723,848
Effect of diluted stock options, warrants and preferred stock (1) (in shares)	[1]
Loss per common share - basic and diluted (in dollars per share)		$ (0.21)	$ (3.01)
[1]	The number of shares underlying options and warrants outstanding as of March 31, 2017 and March 31, 2016 are 1,427,558 and 167,986 respectively. The number of shares underlying the preferred stock as of March 31, 2017 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Valuation Allowance Percentage	100.00%
Income Tax Expense (Benefit)	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards		$ 30,900,000	$ 31,400,000
Operating Loss Carryforwards, Valuation Allowance		10,700,000	11,000,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards		13,000,000	13,200,000
Operating Loss Carryforwards, Valuation Allowance		$ 200,000	$ 200,000

Note 5 - Income Taxes - Compone

Note 5 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Net Operating Loss	$ 10,865,000	$ 10,755,000
Other	343,000	189,000
Total Deferred Tax Asset	11,208,000	10,944,000
Less Valuation Allowance	11,208,000	10,944,000
Net Deferred Income Taxes	$ 0	$ 0

Note 6 - Rent Obligation (Detai

Note 6 - Rent Obligation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation	3 years
Lessee Leasing Arrangements Operating Leases Extension Term	5 years
Operating Leases, Rent Expense	$ 16,895	$ 16,750

Note 6 - Rent Obligation - Rent

Note 6 - Rent Obligation - Rent Obligation (Details)	Mar. 31, 2017USD ($)
2,017	$ 29,250
2,018	$ 3,000

Note 7 - Related Party Transa38

Note 7 - Related Party Transactions (Details Textual) - GLG Pharma, LLC. [Member]	Sep. 20, 2016shares
Stock Expected to be Issued Upon Agreement, Shares	400,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche One	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Two	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Three	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Four	100,000

Note 8 - Retirement Savings P39

Note 8 - Retirement Savings Plan (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%		100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%		4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 9,770	$ 11,117

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual) - $ / shares	Apr. 24, 2017	Mar. 31, 2017	Dec. 31, 2016	Oct. 04, 2016
Common Stock, Par or Stated Value Per Share		$ 0.01	$ 0.01	$ 0.01
Subsequent Event [Member] | Consultant [Member]
Stock Issued During Period, Shares, Issued for Services	100,000
Common Stock, Par or Stated Value Per Share	$ 0.01